Table 2.
Erenumab dispensing patterns and persistence in the full study population and 6-month follow-up sample stratified by persistence
| All patients (N = 9753) | 6-month follow-up patients | |||
|---|---|---|---|---|
| All (N = 4437) | Erenumab persistent (N = 1853) | Erenumab non-persistent (N = 2584) | ||
| Remained on initial dose, n (%) | 8236 (84.4) | 3410 (76.9) | 1261 (68.1) | 2149 (83.2) |
| Switched from initial dose, n (%) | 1517 (15.6) | 1027 (23.1) | 592 (31.9) | 435 (16.8) |
| 70 mg initial dose | n = 6845 (70.2) | n = 3136 (70.7) | n = 1394 (75.2) | n = 1742 (67.4) |
| Switched to 140 mg, n (%) | 1202 (17.6) | 833 (26.6) | 497 (35.7) | 336 (19.3) |
| Time to switch (days) | ||||
| Mean (SD) | 114.2 (65.0) | 131.3 (67.8) | 135.0 (64.9) | 125.8 (71.6) |
| 95% CI | (110.5, 117.9) | (126.7, 135.9) | (129.3, 140.7) | (118.2, 133.5) |
| 140 mg initial dose | n = 2908 (29.8) | n = 1301 (29.3) | n = 459 (24.8) | n = 842 (32.6) |
| Switched to 70 mg, n (%) | 315 (10.8) | 194 (14.9) | 95 (20.7) | 99 (11.8) |
| Time to switch (days) | ||||
| Mean (SD) | 104.3 (71.2) | 125.6 (78.3) | 130.1 (79.7) | 121.3 (77.7) |
| 95% CI | (96.5, 112.2) | (114.5, 136.7) | (114.0, 146.2) | (105.8, 136.8) |
| Erenumab proportion of days covered | 3-month follow-up | |||
| n | 7280 | 4437 | 1853 | 2584 |
| Mean (SD) | 0.80 (0.24) | 0.68 (0.28) | 0.94 (0.07) | 0.48 (0.21) |
| 95% CI | (0.79, 0.80) | (0.67, 0.68) | (0.94, 0.95) | (0.47, 0.49) |
CI confidence interval, SD standard deviation